eXoZymes Inc
EXOZ
$9.76 -2.59% Quote
Exchange NASDAQ Sector Healthcare Industry Biotechnology
Q2 2024
Reported
Published: Jun 30, 2024

Data: Financial Modeling Prep

Company Status Snapshot

Fast view of the latest quarter outcome for EXOZ

Report Date

Jun 30, 2024

Quarter Q2 2024

Revenue

N/A

YoY: N/A

EPS

N/A

YoY: N/A

Market Move

-2.59%

Previous quarter: Q1 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Net Income

-1.36M

YoY: -664.0%

N/A

— N/A
EXOZ
Company EXOZ

Swipe to view all report sections

Executive Summary

eXoZymes Inc (EXOZ) delivered a QQ2 2024 quarter characterized by no reported revenue and a pronounced cash burn, consistent with a capital-intensive, platform-focused biotechnology company at an early stage. R&D and G&A expenses totaled $1.33 million, with depreciation adding another $0.068 million, yielding an EBITDA of approximately negative $1.260 million and a net loss near $1.3605 million for the quarter. Operating cash flow was negative at roughly $2.54 million, driven by working capital outflows and ongoing investment in the SimplePath platform. The balance sheet remains liquidity-constrained, with a current ratio of 0.36, negative equity (-$2.26 million), and a total debt load of about $4.37 million against total assets of ~$4.05 million. Net debt stood at ~$4.22 million. These dynamics imply a shortened runway absent external funding or milestone-driven monetization of the platform. While the dataset does not include an earnings call transcript, the quarter reinforces a high-risk, high-uncertainty profile typical of early-stage biotechnologies, where value creation hinges on eventual clinical or licensing milestones and successful capital markets access. Investors should monitor cash runway, potential financing events, and any strategic partnerships or licensing deals tied to SimplePath that could unlock near-term value.

Key Performance Indicators

Operating Income
Decreasing
-1.33M
QoQ: -31.75% | YoY: -646.02%
Net Income
Decreasing
-1.36M
QoQ: -34.91% | YoY: -664.00%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 0.00 -0.28 +0.0% View
Q4 2024 0.00 0.00 +0.0% View
Q3 2024 0.00 -0.20 +0.0% View
Q2 2024 0.00 0.00 +0.0% View
Q1 2024 0.00 -0.12 +0.0% View